Table 2.
Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.
| Anti-diabetic drug(s) | No of patients | Presence of co-morbidities* |
|---|---|---|
| Glibenclamide only | 1 | 1 |
| Insulin only | 4 | 2 |
| Insulin + Gliclazide | 1 | 0 |
| Metformin + Acarbose + Glibenclamide | 2 | 1 |
| Metformin + Acarbose + Gliclazide + Insulin | 1 | 1 |
| Metformin + Glibenclamide | 42 | 25 |
| Metformin + Gliclazide | 10 | 8 |
| Metformin + Gliclazide + Pioglitazone | 3 | 3 |
| Metformin + Glimepiride | 19 | 16 |
| Metformin + Glimepiride + Pioglitazone | 2 | 2 |
| Metformin + Insulin | 3 | 2 |
| Metformin + Insulin + Glibenclamide | 2 | 1 |
| Metformin + Pioglitazone | 1 | 1 |
| Metformin + Vidagliptin | 1 | 1 |
| Metformin only | 18 | 17 |
*
The presence of co-morbidities indicates that there are other non-hypoglycaemic agents on the patient's prescription.